Can anyone confirm that this gen 1 fpp and also the gen 2 fpp are not using viral vector to enter cells. I am assuming not and if that is the case then obviously this could be a very big thing as previously discussed many companies lost share price when their viral vector or aav method failed in trials in vivo due to immune response?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
-0.020(1.56%) |
Mkt cap ! $737.8M | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.29 | $1.25 | $4.616M | 3.649M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19940 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 1008 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |